📰 Prime Editing News
Prime Editing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Prime Editing. Real-time updates on events, politics, business and more.
May 29, 2024
CellEDIT Service represents a novel workflow leveraging FluidFM-mediated intranuclear nanoinjection of CRISPR/Cas9 components into single cells.Control of the amount and stoichiometry of RNP complexes
May 29, 2024
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells....
May 23, 2024
Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.
April 10, 2024
Genome Engineering Editing is a modern molecular biology technology that involves targeted modifications to the genome of an organism to change the sequence of a target gene or regulate its expression. This technology is largely based on genome editing tools such as CRISPR-Cas9, which allows scientists to precisely add, delete or replace an organism-s genes. According to the new market research report “Global Genome Engineering Editing Market Report 2023-2029”, published by QYResearc
April 9, 2024
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The
February 28, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that...
February 20, 2024
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new c...
February 15, 2024
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of...
February 15, 2024
CAMBRIDGE, Mass., Feb. 14, 2024 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the...
February 1, 2024
CAMBRIDGE, Mass., Feb. 01, 2024 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that...